Chengde Wu

Discovery of TBC11251, a Potent, Long Acting, Orally Active Endothelin Receptor-A Selective Antagonist

Chengde Wu, Ming Fai Chan, Fiona Stavros et al. · Journal of Medicinal Chemistry · 1997 · 124 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery, Modeling, and Human Pharmacokinetics of<i>N</i>-(2-Acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a Second Generation, ET_ASelective, and Orally Bioavailable Endothelin Antagonist

Chengde Wu, E. Radford Decker, Natalie Blok et al. · Journal of Medicinal Chemistry · 2004 · 105 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Genetic Algorithm-Optimized QSPR Models for Bioavailability, Protein Binding, and Urinary Excretion

Junmei Wang, George A. Krudy, Xiang‐Qun Xie et al. · Journal of Chemical Information and Modeling · 2006 · 61 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

TBC3711, an ETA Receptor Antagonist, Reduces Neonatal Hypoxia-Induced Pulmonary Hypertension in Piglets

Thérèse Perreault, John W. Berkenbosch, Keith J. Barrington et al. · Pediatric Research · 2001 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +14

Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma

Chengde Wu, Xiang Rao, Wei Lin · Cancer Medicine · 2020 · 36 citations · Full text

Medicine, Immunology, Oncology +17